Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accelerated Approval Should Be “Conditional,” Panel Says

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s accelerated approval process should be renamed “conditional approval,” according to members of FDA oncology advisory committee.

You may also be interested in...



“Conditional” Approval System Could Require Comparative Confirmatory Trials

NIH staffer suggests sponsors could be required to submit comparative effectiveness data after receiving conditional approval.

“Conditional” Approval System Could Require Comparative Confirmatory Trials

NIH staffer suggests sponsors could be required to submit comparative effectiveness data after receiving conditional approval.

Submitted Data Confirm Doxil's Clinical Benefit, J&J Maintains

FDA's Oncologic Drugs Advisory Committee will review on Nov. 8 unfulfilled accelerated approval trial commitments for products approved before 2002.

Related Content

Topics

UsernamePublicRestriction

Register

PS061359

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel